Emma Walmsley, GlaxoSmithKline CEO (Credit: Fang Zhe/Xinhua/Alamy Live News)

Ac­tivist in­vestor El­liott in talks with oth­er Glax­o­SmithK­line in­vestors about re­plac­ing Em­ma Walm­s­ley, spin­ning off vac­cine busi­ness — re­port

As Em­ma Walm­s­ley re­veals de­tails this Wednes­day about the up­com­ing split of Glax­o­SmithK­line’s phar­ma and con­sumer units, some tough ques­tions may be com­ing her way.

El­liott Man­age­ment, the ac­tivist in­vestor that’s pre­vi­ous­ly threat­ened an at­tack on GSK (but even­tu­al­ly backed off), is float­ing more rad­i­cal changes like re­plac­ing the CEO, fur­ther break­ing up the com­pa­ny and spin­ning out the vac­cine unit, or re­view­ing the fo­cus on can­cer drugs, the Fi­nan­cial Times re­port­ed.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.